1-4 of 4
Jürgen Moll
Close
Sort by
Journal Articles

Efficacy of the Plk Inhibitor Volasertib in Preclinical Models of AML

Dorothea Rudolph, PhD, Christoph Albrecht, Lena Geiselmann, Maria Antonietta Impagnatiello, PhD, Pilar Garin-Chesa, MD PhD, Andreas Wernitznig, PhD, Jürgen Moll, PhD, Norbert Kraut, PhD
Journal: Blood
Blood (2014) 124 (21): 2307.
https://doi.org/10.1182/blood.V124.21.2307.2307
Published: 2014
Journal Articles

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller, Riccardo Colombo, Alessio Graziano, Enrico Pesenti, Daniel Benten, Carsten Bokemeyer, Walter Fiedler, Jürgen Moll, Tim H. Brümmendorf
Journal: Blood
Blood (2008) 111 (8): 4355–4364.
https://doi.org/10.1182/blood-2007-09-113175
Published: 2008
Journal Articles

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D, Gunhild Keller, M.D., Jens Panse, M.D., Mirja Bernhardt, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.
Journal: Blood
Blood (2007) 110 (11): 4568.
https://doi.org/10.1182/blood.V110.11.4568.4568
Published: 2007
Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.
Journal: Blood
Blood (2007) 110 (11): 1042.
https://doi.org/10.1182/blood.V110.11.1042.1042
Published: 2007